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1. LIST OF ABBREVIATIONS 
PG - Proteoglycan 
GAG - Glycosaminoglycan 
β4GalT7 - β-1,4-Galactosyltransferase 7 
CS/DS - Chondroitin sulfate/dermatan sulfate  
HS - Heparan sulfate 
XylNap - 2-Naphthyl β-D-xylopyranoside 
Nap - Naphthyl 
KOAc - Potassium Acetate 
Ac20 - Acetic anhydride 
BF3·OEt2 - Boron trifluoride diethyl etherate 
Et3N - Triethylamine 
N2 - Nitrogen gas 
R.t. - Room temperature 
NaOMe - Sodium methoxide 
MeOH - Methanol 
CSA - Camphorsulfonic acid  
DMF - Dimethylformamide  
Anhyd. - Anhydrous 
DMSO - Dimethylsulfoxide 
THF - Tetrahydrofuran 
CS2 - Carbon disulfide 
MeI - Iodomethane 
AIBN - 2,2’-Azobis(2-methylpropionitrile) or a,a’-Azoisobutyronitrile 
n-Bu3SnH - Tributyltin hydride 
AcOH - Acetic acid 
Tf2O - Trifluoromethanesulfonic anhydride (triflic anhydride) 
DAST - Diethylaminosulfur trifluoride 
NMR - Nuclear magnetic resonance 
Ppm - Parts per millon 
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TLC - Thin layer chromatography 
UV - Ultra Violet  
EtOH - Ethanol 
Sat. aq. - Saturated aqueous 
EtOAc - Ethyl acetate 
Dist. - Distilled 
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2. ABSTRACT 
The aim of this thesis was to synthesize various β-D-ribopyranoside derivatives with different 
C-4 functional groups, using D-xylose as the starting material. The desired modifications 
were deoxygenation, fluorination, methylation and epimerization of the C-4 hydroxyl group. 
Methylation provided the best results with the final product being successfully synthesized. 
Deoxygenation was also achieved but the final de-protection step was not carried out. 
Epimerization was attempted using two different methods but without success, firstly 
probably due to the high energetic favorability of having the hydroxyl group in the equatorial 
position, and secondly due to harsh reaction conditions causing the cleavage of the hydroxyl 
group. Fluorination was not attempted.   
 
 
 
3. INTRODUCTION 
After cardiovascular diseases, cancer represents the second leading cause of death in highly 
developed countries.1 It constitutes a major burden on modern societies and estimates show 
that if rapid improvements in medical treatments aren’t made it could soon become the 
world’s main cause of human mortality. A current development in cancer research is the 
interest in D-xylose (fig. 1) as a precursor for anti-cancer agents due to its biological 
importance in mammals and its availability in nature.2 
 
(Open chain form) (Cyclic form) (Chair conformation)
1
D-xylose
2
β-D-xylopyranose β-D-xylopyranose
3
 
Fig. 1. D-xylose in its open chain and pyranose form (only the pyranose form of sugars will be considered in the 
rest of the thesis). 
 
                                                          
1 Rozpedek, W.; Pytel, D.; Mucha, B.; Leszczynska, H.; Diehl. J. A.; Majsterek, I. The Role of the 
PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress, Curr. 
Mol. Med., 2016, 16, 533-544 
2 Thorsheim, K.; Siegbahn, A.; Johnsson, R. E.; Stålbrand, H.; Manner, S.; Widmalm, G.; Ellervik, U. Chemistry of 
Xylopyranosides, Carbohydr Res., 2015, 418, 65-88 
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3.1. Xylose, proteoglycan and cancer  
Xylose is a sugar which is largely isolated from wood and is hence regularly referred to as 
wood sugar. It is one of the most common carbohydrates found on Earth and is also present in 
proteoglycans (PGs). PGs are produced by mammalian cells and are important for a variety of 
biological processes.3 The PG is made up of a core protein attached to various GAG 
(Glycosaminoglycan) chains via a xylose-bearing polysaccharide linker (fig. 2).  
 
 
Fig. 2. The structure of proteoglycan (Gal = Galactopyranose, Xyl = Xylopyranose). 
PG/GAG expression is a crucial part of the pathobiology of every stage in cancer progression 
including tumor invasion, proliferation and metastasis. One enzyme that plays a crucial role in 
the biosynthesis of PGs and GAGs is β4GalT7 (β-1,4-Galactosyltransferase 7). It has been 
shown that controlling the expression of this enzyme subsequently controls PG/GAG 
expression, thus making the enzyme a promising target in the development of anticancer 
agents.4  
 
3.2. β4GalT7 in biosynthesis and inhibition 
β4GalT7 is an enzyme which is essential in the biosynthesis of CS/DS (chondroitin 
sulfate/dermatan sulfate) and HS (heparan sulfate) GAG chains. Xylosyltranferase initiates 
the biosynthesis by xylosylating the serine residue on the core protein (fig. 2) before β4GalT7 
galactosylates the xylosylated protein. Further enzymatic reactions are carried out until a 
                                                          
3 Siegbahn, A.; Manner, S.; Persson, A.; Tykesson, E.; Holmqvist, K.; Ochocinska, A.; Rönnols, J.; Sundin, A.; 
Mani, K.; Thorsson, G. W.; Widmalm, G.; Ellervik, U. Exploration of the active site of β4GalT7: Modifications of 
the aglycon of aromatic xylosides, Org. Biomol. Chem., 2015, 13, 3351-3362 
4 Siegbahn, A.; Manner, S.; Persson, A.; Tykesson, E.; Holmqvist, K.; Ochocinska, A.; Rönnols, J.; Sundin, A.; 
Mani, K.; Thorsson, G. W.; Widmalm, G.; Ellervik, U. Rules for priming and inhibition of glycosaminoglycan 
biosynthesis; probing the β4GalT7 active site, Chem. Sci, 2014, 5, 3501-3508 
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polysaccharide linker (fig. 2) is formed, which serves as the branching point for CS/DS and 
HS biosynthesis. 
Alternatively, the biosynthesis can be initiated by an exogenous addition of β-D-
xylopyranosides carrying hydrophobic aglycons. One such compound is 2-Naphthyl β-D-
xylopyranoside (XylNap) (fig. 3) which can act as a β4GalT7 acceptor substrate in the initial 
galactosylation step, resulting in GalXylNap (i.e. XylNap with a galactose substrate added to 
it).  
 
4GalT7
Galactose
XylNap GalXylNap  
Fig. 3. GalXylNap made from the galactosylation of XylNap by β4GalT7. 
However, the β4GalT7 binding pocket is very narrow with a specific number of important 
hydrogen bonds. This means that inhibitors of galactosylation can be rendered by modifying 
the xylose moiety of the xylopyranoside, which can be a valuable tool for exploring PG and 
GAG biosynthesis and for developing anti-tumor agents. 
 
3.3. Xylose synthesis 
The focus of this thesis will be the modification of the xylose moiety in the xyloside. 
Compared to various carbohydrates, such as galactose and glucose, xylose doesn’t have a 
primary hydroxyl group and is therefore synthetically challenging.5 Additionally, all three 
remaining non-orthogonal hydroxyl groups are secondary and of nearly equivalent reactivity 
(fig. 4). Small differences do exist though with the C4-OH usually being considered the most 
reactive and the 2-OH being the second most reactive. 
 
 
 
 
 
 
                                                          
5 Manner, S.; Ellervik, U. Release of Ring Strain as Driving Force for Inversion of Stereochemistry – Application 
to the Synthesis of Ribopyranosides from Xylopyranosides, Synlett, 2014, 25, 1271-1274 
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β-D-glucopyranose
4
β-D-galactopyranose
5
β-D-xylopyranose
3
 
 
 
Fig. 4. Hydroxyl groups contributing to the synthetic challenges of xylose compared to glucose and galactose. 
Nevertheless, it is possible to achieve selective epimerization of the C3 hydroxyl group, 
turning the xylopyranoside into a ribopyranoside. This is a desired transformation in this 
thesis and is done via a Swern oxidation-epimerization-reduction sequence (fig. 5). The 
driving force for the epimerization is the release of ring strain when going to a 1,2-cis-acetal 
from a 1,2-trans-acetal.  
 
Nap =
Swern
oxidation
1,2-trans-acetal
6 7
1,2-cis-acetal
8
 
Fig. 5. Swern oxidation leading to the release of ring strain when going from 1,2-trans-acetal to 1,2-cis-acetal. 
 
3.4. Synthetic protocol 
A synthetic protocol based on selective benzylation and acetal protection was developed by 
Siegbahn et al. (2011) for the modification of the hydroxyl groups in xylose. Twelve XylNap 
analogs were synthesized where each hydroxyl group was replaced by hydrogen 
(deoxygenated), methoxy or fluoro or had been epimerized.  
A similar protocol was explored in this thesis. Firstly, the hydroxyl group on position C3 on 
the xylose moiety was to be epimerized. The hydroxyl group on C4 was then to be replaced 
by hydrogen, fluorine, a methoxy group and be epimerized, resulting in 4 XylNap analogs 
(fig. 6). The ability of the analogs to inhibit β4GalT7 and subsequent PG/GAG expression can 
then be explored, potentially leading to the development of an anticancer agent. 
No primary hydroxyl group! 
Nearly equivalent reactivity 
8 
 
 
 
Fig. 6. Synthetic protocol of compounds intended to be synthesized in this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epimerized C3 hydroxyl 
9a: R = OMe 
9b: R = epi-OH 
9c: R = F 
9d: R = H 
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4. RESULTS & DISCUSSION 
The following scheme summarizes the synthetic procedures that were intended to be carried 
out in the thesis: 
3 10 11
12
6
7
8
9a
9b
9c
9d
13
14a
14b
14c
14d
 
 Scheme 1. Schematic overview of synthetic work.   
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4.1.XylNap (2-Naphthyl β-D-xylopyranoside) synthesis 
Synthesis of XylNap (sch. 2), 12, was performed successfully without any significant 
problems. Peracetylation gave yields slightly lower than reported values (37% compared 
to 50%) while glycosylation of 2-naphthol gave 11 in good yield as expected. The final 
de-protection step also gave XylNap in an expected good yield of 76%. 
BF
3
.OEt
2
2-naphthol
Et
3
N
NaOMe
MeOH
KOAc
Ac2O
3 10
1112  
 Scheme 2. Synthesis of 2-Naphthyl β-D-xylopyranoside (XylNap) from D-Xylose.  
 
4.2.From XylNap to 2,3-acetal protected RiboNap 
The acetal isopropylidene is used to protect the 2-OH and 3-OH of XylNap in order to 
leave the C4-OH free to be modified at a later step. The reaction gave 6 and 15 in a ratio 
of 74:26 which is consistent with the ratio of 77:23 published by S. Manner and U. 
Ellervik (2014) (sch. 3). A fair yield of 42% for 6 was slightly lower than the published 
value of 52%, probably due to product dilution during flash chromatography resulting in 
some of the product remaining in the column.  
2-methoxypropene
CSA
DMF anhyd.
74%
12 6
26%
15
  
 Scheme 3. Addition of isopropylidene protecting group giving both the 2,3- and 3,4-acetal. 
As explained by S.Manner and U. Ellervik (2014), the strategy for epimerizing the 3-
oxygen of the xylopyranoside, and turning it into a ribopyranoside, involves the oxidation 
of the C4-OH under Swern conditions and the subsequent release of ring strain through 
the epimerization of the 3-oxygen (sch. 4). 6 was successfully oxidized and epimerized to 
7, but this compound was not isolated. It was instead immediately reduced to give 8 in a 
very good yield of 83%. 
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NaBH
4
H
2
O
6
i) Oxalyl chloride
DMSO
ii) Et
3
N
7 8  
 Scheme 4. Swern oxidation-epimerization-reduction sequence to give ribopyranoside. 
 
4.3.Modifications of C4-OH 
4.3.1. Methylation    
Sodium hydride is used to deprotonate the C4 hydroxyl group of 8 before methylation by 
methyl iodide to give 14a (sch. 5).  A fair yield of 57% was obtained which is similar to 
published values of 66% for the same reaction with 8 having two benzyl protecting groups 
instead.  
14a was then deprotected by AcOH to give 9a and the product was identified via 1H NMR 
and HRMS. 
NaH
MeI
70% AcOH
40oC, 6h
8 14a 9a  
 Scheme 5. C4-OH methylation followed by acetal de-protection.   
 
4.3.2. Epimerization 
4.3.2.1. Standard method 
9b is synthesized in two steps (sch. 6). Firstly, 8 is turned into a triflate (fig. 7), 17, by 
trifluoromethane sulfonic anhydride. The triflate was identified by 1H NMR and then 
immediately substituted in the presence of cesium acetate with the intention to give 14b. 
However, 1H NMR indicates the synthesis of a different compound. The two protons at 
2.22 and 1.99 ppm indicate that the C4-OH has been deoxygenated, resulting in 14d (sch. 
8). The C4 oxygen was probably cleaved due to a prolonged reaction time of 3 days with 
cesium acetate and this is further suggested by multiple compounds on the TLC plate 
obtained after the reaction. Only one isolated compound was detectable and this product 
was obtained in trace amounts. 9b was not synthesized. 
 
 
12 
 
i) Tf2O,
pyridine
ii) CsOAc
8
70% AcOH
40oC, 6h
14b 9b  
 Scheme 6. Standard epimerization of C4-OH followed by acetal de-protection.  
 
17  
Fig. 7. Molecular structure of the triflate intermediate 17. 
 
4.3.2.2. Microwave method 
8 was first heated under microwave radiation and oxidized by DMSO to give 7, which 
was then reduced by NaBH4 with the intention to give 14b (sch. 7). 
1H NMR showed that 
8, instead of 14b, had formed after the reduction of 7. This is probably because having the 
OH group in an equatorial position makes it much more electron withdrawing than when 
in an axial position.6 This effect is further enhanced by the axially positioned C3 oxygen. 
If the C4 oxygen is in an axial position as well it will make the molecule very unstable. 
This will cause the OH group to return to its preferred equatorial position and hence result 
in the regeneration of 8. 9b (sch. 6) was not synthesized. 
Ac
2
O, DMSO
80oC, 7 min
NaBH
4
78 14b  
 Scheme 7. Epimerization of C4-OH via the microwave method.   
 
                                                          
6 Rönnols, J.; Manner, S.; Ellervik, U.; Widmalm, G. Conformational effects due to stereochemistry and C3-
substituents in xylopyranoside derivatives as studied by NMR spectroscopy, Org. Biomol. Chem., 2014, 12, 
8031-8035   
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4.3.3. Deoxygenation  
The C4-OH of 8 is deoxygenated in two steps. The first step results in the formation of a 
xanthate, 13, using methyl iodide and carbon disulfide (sch. 8). The product yield was 
poor at 34% and the compound was identified using 1H NMR but the peak-values were 
only used to quickly identify the product before the entire amount was used in the next 
step.  
In the second step AIBN and n-Bu3SnH is used to deoxygenate the xanthate intermediate 
to give 14d (sch. 8). However, 1H NMR indicates that a different product was synthesized. 
The peak at 2.61 ppm suggests the presence of a methoxy group on C4. Comparing with 
the 1H NMR of 14a (sch. 5), the signal is further upfield while the multiplet signal for C4-
H at 6.30-6.26 ppm is further downfield for the intended product. This indicates that the 
methoxy group in the intended product is in an axial position, ultimately giving 16 (fig. 7). 
The isolation of this substrate could have occurred as a consequence of harsh reflux 
conditions giving multiple products, as shown on the TLC plate, followed by the solitary 
detection of the most abundant compound. The product yield was also very poor only 
giving trace amounts, further indicating that decomposition took place during reflux. This 
was however not confirmed. 
NaH, CS2
MeI
8 13
14d9d
70% AcOH
40oC, 6h
AIBN
n-Bu3SnH
 
 Scheme 8. Xanthate formation followed by deoxygenation and final acetal de-protection. 
 
16  
Fig. 7. Molecular structure of the unintended product 16 (2-Naphthyl-2,3-O-isopropylidene-4-epimethoxy β-D-
ribopyranoside). 
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5. CONCLUSION AND FUTURE WORK 
XylNap was successfully synthesized without any significant problems. Subsequent 2,3-acetal 
protection and C3 epimerization to RiboNap also proceeded well with yields consistent with 
published values. The modification of C4-OH was more problematic with three of the four 
reactions giving unintended products. The attempted deoxygenation gave an axial methoxy 
group instead due to unfavorable reflux conditions, while attempted epimerization either gave 
the starting material back when oxidizing under microwave radiation or gave a deoxygenated 
product due to a prolonged reaction time of 3 days after the addition of cesium acetate. 
Methylation of C4-OH was successful however with a fair yield of 57%. Subsequent de-
protection of the methylated compound was also successful, giving one of the intended β-D-
ribopyranoside derivatives.  
Future work should focus on the epimerization of the C4 hydroxyl group as it was shown to 
be a problematic transformation. Methods that take into account the large difference in 
electronegativity between the axial and equatorial positions is advocated as well as 
appropriate catalysts and reactionary conditions as some of the substrates were shown to be 
sensitive to the environment. Having appropriate reflux conditions during C4 deoxygenating 
is also encouraged. 
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6. EXPERIMENTAL 
6.1. General methods 
Oven dried glassware was used for all air- and moisture-sensitive reactions and they were 
carried out under a dry nitrogen atmosphere. All NMR spectra were recorded using a Bruker 
AVANCE II spectrometer operating at 296 K. All chemical shifts are indicated by ppm values 
downfield from Me4Si, with reference to the following residual internals; MeOH-d4 (3.31), 
C6H6-d6 (7.16) and CHCl3-d (7.24). Values for coupling constants are given in Hz. COSY (2D 
homonuclear shift correlation) was used to assign certain 1H NMR spectra. Monitoring of 
reactions was done by TLC using alumina plates that were coated with silica gel and the 
compounds were visualized by staining with para-anisaldehyde or by UV-light. Silica gel (35-
70 µm, 60 Å) was used when performing flash chromatography. Solvents were only dried 
prior to use if stated. No further purification was performed on purchased reagents.    
 
 
6.2. Synthesis 
6.2.1. 1,2,3,4-Tetra-O-acetyl β-D-xylopyranose (10)  
KOAc (12 g, 123 mmol) was suspended in Ac20 (165 ml) and the mixture was heated 
to 140 0C. (1) (β-D-xylose) (15 mg, 104 mmol) was added in equal proportions over 30 
min before being left to react for 2h. The mixture was poured onto ice-water (400 ml), 
the organic phase was extracted with CH2Cl2 (3 x 250 ml) and the combined phases 
were washed with NaHCO3 (400 ml). The washed solution was dried with MgSO4 and 
charcoal (4 teaspoons) was added. The mixture was stirred for 30 min before being 
filtered through a pile of SiO2 which was then eluted with CH2Cl2. The solvent was 
evaporated and the precipitate was co-evaporated with toluene (twice) before being 
recrystallized from EtOH to give 10 (12 g, 38 mmol, 37%). TLC (Hep/EtOAc 1:1, r.f. 
= 0.46); 1H NMR (CDCl3): δ 5.71 (d, 1H, J = 7.2, C1-H), 5.20 (dd, 1H, J = 8.4, 8.4, 
C3-H), 5.04 (dd, 1H, J = 8.4, 6.8, C2-H), 4.98 (ddd, 1H, J = 8.4, 8.0, 5.2, C4-H), 4.15 
(dd, 1H, J = 12.0, 4.8, C5-H), 3.52 (dd, 1H, J = 12.0, 8.4, C5-H), 2.11 (s, 3H, C1Ac-
H), 2.05 (s, 9H, Ac-H).  
 
6.2.2. 2-Naphthyl-2,3,4-O-acetyl β-D-xylopyranoside (11) 
10 (8.0 g , 25.1 mmol) and 2-naphthol (5.4 g, 37.7 mmol) were dissolved in dry 
CH2Cl2 (80 ml) and Et3N (1.8 ml, 12.6 mmol) was added followed by a dropwise 
addition of BF3·OEt2 (17ml, 62.8 mmol) and the solution was left to stir for 3h. The 
reaction was quenched with sat. aq. NaHCO3 (125 ml) and the organic phase was 
extracted with EtOAc (2 x 250 ml). The combined phases were dried with Na2SO4, the 
solvent was evaporated and the resulting precipitate was recrystallized from EtOH to 
give 11 (6.9 g, 17.2 mmol, 68%). TLC (Hep/EtOAc 1:1, r.f. = 0.73); 1H NMR 
(CDCl3): δ 7.80-7.73 (m, 3H, ArH), 7.48-7.44 (m, 1H, ArH) 7.41-7.36 (m, 2H, ArH) 
7.18 (dd, 1H, J = 9.2, 2.4, ArH) 5.34 (d, 1H, J = 6.0, C1-H), 5.29-5.22 (m, 2H, C2&3-
H), 5.04 (ddd, 1H, J = 7.6, 7.4, 4.8, C4-H), 4.28 (dd, 1H, J = 12.4, 4.4, C5-H1), 3.60 
(dd, 1H, J = 12.0, 7.6, C5-H2), 2.10 (s, 9H, Ac-H). 
16 
 
6.2.3. 2-Naphthyl β-D-xylopyranoside (12)  
11 (6.5 g, 16.2 mmol) was suspended in MeOH (54 ml), 1M NaOMe (2.7 ml, 52 
mmol) was added and the mixture was left to stir for 1h. AcOH (90%) was then added 
dropwise until pH 6 and the solvent was evaporated. The precipitate was co-
evaporated with toluene (4 x 125 ml) and recrystallized from EtOH to give 12 (3.4 g, 
12.4 mmol, 76%). TLC (CH2Cl2/MeOH 10:1, r.f. = 0.61); 
1H NMR (MeOH-d4): δ 
7.79-7.75 (m, 3H, ArH), 7.45-7.41 (m, 2H, ArH), 7.37-7.33 (m, 1H, ArH), 7.26 (dd, 
1H, J = 9.2, 2.4, ArH), 5.03 (d, 1H, J = 7.2, C1-H), 3.98 (dd, 1H, J = 11.6, 5.2, C5-H), 
3.63-3.58 (m, 2H, C-H), 3.51-3.45 (m, 2H, C-H). 
 
6.2.4. 2-naphthyl-2,3-O-isopropylidene β-D-xylopyranoside (6) 
12 (2.00 g, 7.24 mmol) and CSA (0.25 g, 1.09 mmol) were suspended in anhyd. DMF 
(12 ml). 2-methoxypropene (0.47 ml, 4.89 mmol) was added every 20 min in 4 
portions and 30 min after the last addition, Et3N (4 ml) was added. The solvent was 
evaporated, the precipitate was co-evaporated with toluene (10 times) before the crude 
was purified via flash chromatography (SiO2, petroleum ether (40-60):diethyl ether + 
1% Et3N 2:1  1:1) to give 6 (0.96 g, 3.03 mmol, 42%). TLC (petroleum ether:diethyl 
ether 1:3 + 1% Et3N, r.f. = 0.50); 
1H NMR (C6D6): δ 7.61-7.53 (m, 3H, ArH), 7.49 (d, 
1H, J = 9.0, Ar-H), 7.32 (dd, 1H, J = 9.0, 2.5, Ar-H), 7.25 (ddd, 1H, J = 8.0, 6.5, 1.0, 
Ar-H), 7.17 (ddd, 1H, J = 8.0, 6.5, 1.0, Ar-H), 5.28 (d, 1H, J = 7.5, C1-H), 3.81 (dd, 
1H, J = 12.0, 5.0, C5-H), 3.76 (dd, 1H, J = 9.5, 7.5, C2-H), 3.66 (ddd, 1H, J = 8.5, 6.5, 
5.0, C4-H), 3.57 (dd, 1H, J = 9.5, 9.0, C3-H), 3.12 (dd, 1H, J = 12.0, 6.5, C5-H), 1.40 
(s, 6H, i.p.-H). 
 
6.2.5. 2-naphthyl-2,3-O-isopropylidene β-D-ribopyranoside (8) 
Anhyd. DMSO (1.05 ml, 14.22 mmol) was added to a solution of 2M oxalyl chloride 
(3.6 ml, 7.1 mmol) at -78 oC and stirred for 1h. 6 (0.75 g, 2.37 mmol) in anhyd. 
CH2Cl2 (60 ml) was then added dropwise and stirred for 2h followed by Et3N (5 ml). 
After an additional 30 min the solution was allowed to reach rt. and left to stir 
overnight. MeOH (50 ml) was then added and the resulting solution was cooled to 0 
oC followed by the addition of NaBH4 (0.25 g, 6.40 mmol). After 5h stirring the 
reaction mixture was quenched with H2O, allowed to reach room temperature and the 
organic phase was extracted with CH2Cl2 (4 x 110 ml). The organic phase was dried 
with NaSO4 and the solvent was evaporated before the crude was purified via flash 
chromatography (Hep/EtOAc 7:3) to give 8 (0.62 g, 1.96 mmol, 83%). TLC 
(Hep/EtOAc 1:1, r.f. = 0.49); 1H NMR (MeOH-d4): δ 7.80-7.76 (m, 3H, ArH), 7.46-
7.41 (m, 2H, ArH), 7.35 (ddd, 1H, J = 8.0, 6.8, 1.2, ArH), 7.21 (dd, 1H, J = 8.8, 2.4, 
ArH), 5.40 (d, 1H, J = 4.0, C1-H), 4.63 (dd, 1H, J = 6.0, 3.6, C3-H), 4.35 (dd, 1H, J = 
6.0, 4.0, C2-H), 4.24 (ddd, 1H, J = 9.6, 6.4, 3.6, C4-H), 3.83-3.74 (m, 2H, C5-H), 1.55 
(s, 3H, i.p.-H), 1.43 (s, 3H, i.p.-H). 
 
6.2.6. 2-Naphthyl-2,3-O-isopropylidene-4-methoxy β-D-ribopyranoside (14a)  
8 (150 mg, 474 µmol) was dissolved in dist. DMF (4 ml), the solution was chilled to 0 
oC and NaH (40 mg, 948 µmol) was added. The solution was stirred for 20 min, MeI 
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(60 µL, 948 µmol) was added and the reaction mixture was allowed to reach room 
temperature before being left to stir overnight. The mixture was again chilled to 0 oC, 
NaH (19 mg, 474 µmol) was added, the mixture was stirred for another 15 min and 
MeI (30 µL, 474 µmol) was added. The reaction mixture was allowed to reach rt. and 
stirring continued for 2h 30 min before the reaction was quenched with sat. aq. NH4Cl. 
The organic phase was extracted with CH2Cl2 (2 x 10 ml), washed with brine (12 ml), 
dried with NaSO4 and the solvent was evaporated. The crude was then purified via 
flash chromatography (Hep/EtOAc 5:1) to give 14a (90 mg, 272 µmol, 57%). TLC 
(Hep/EtOAc 2:1, r.f. = 0.40); 1H NMR (CDCl3): δ 7.79-7.74 (m, 3H, ArH), 7.45 (ddd, 
1H, J = 8.4, 7.2, 1.6, ArC5/6-H), 7.41 (d, 1H, J = 2.0, ArC1-H), 7.37 (ddd, 1H, J = 8.0, 
6.8, 1.2, ArC5/6-H), 7.22 (dd, 1H, J = 8.8, 2.4, ArC2-H), 5.38 (d, 1H, J = 3.6, C1-H), 
4.76 (ddd, 1H, J = 4.0, 4.0, 2.4, C3-H), 4.38 (dd, 1H, J = 6.4, 3.6, C2-H), 3.96 (m, 2H, 
C5-H), 3.83 (m, 1H, C4-H), 3.51 (s, 3H, OMe), 1.60 (s, 3H, i.p.-H1), 1.45 (s, 3H, i.p.-
H2); 
13C NMR (CDCl3): δ 129.6, 127.8, 127.3, 126.6, 124.5, 118.9, 110.8, 98.4, 76.0, 
73.0, 72.1, 60.8, 57.9, 27.2, 25.6; HRMS calcd for C19H22O5Na
+ [M+Na]: 353.1365; 
found: 353.1364. 
 
6.2.7. 2-Naphthyl-4-methoxy β-D-ribopyranoside (9a) 
14a (84 mg, 254 µmol) was dissolved in EtOAc (40 ml), H20 (6.5 ml) and 90 % 
AcOH (23 ml) was added and the solution was stirred for 4h at 40 oC. Toluene (25 ml) 
was added and the solvent was evaporated to give crude (74 mg). 1H NMR showed 9a 
with some impurities. No further purification was done. TLC (CH2Cl2/MeOH 20:1, r.f. 
= 0.61); 1H NMR (MeOD): δ 7.77 (dd, 3H, J = 13.6, 9.2, ArH), 7.45-7.41 (m, 2H, 
ArH), 7.37-7.32 (m, 1H, ArH), 7.24 (dd, 1H, J = 8.8, 2.4, ArH), 5.55 (d, 1H, J = 4.4, 
C1-H), 4.22 (dd, 1H, J = 3.2, 3.2, C3-H), 3.95 (dd, 1H, J = 12.0, 5.6, C5-H), 3.84 (dd, 
1H, J = 12.4, 2.8, C5-H), 3.77 (dd, 1H, J = 4.0, 3.6, C2-H), 3.57 (ddd, 1H, J = 5.6, 3.2, 
2.4, C4-H), 3.48 (s, 3H, MeO); HRMS calcd for C16H18O5Na
+ [M+Na]: 313.1052; 
found: 313.1052.  
 
6.2.8. 2-Naphthyl-2,3-O-isopropylidene-4-epi β-D-ribopyranoside (14b) (standard method) 
8 (60 mg, 285 µmol) was dissolved in dry CH2Cl2 (3.6 ml) and the solution was 
chilled to -10 oC. Tf2O (50 µL, 285 µmol) was added followed by a slow addition of 
pyridine (50 µL, 570 µmol) before the reaction mixture was left to stir for 3h. The 
mixture was quenched with 0.5 N HCl (3 ml), firstly washed with sat. aq. NaHCO3 (8 
ml) and then brine (10 ml). The resulting solution was dried with Na2SO4 and the 
solvent was evaporated, leaving a precipitate which was dissolved in dry DMF (6 ml). 
Cesium acetate (149 mg, 760 µmol) was added and the solution was heated to 50 oC 
and left to stir overnight. H2O (15 ml) was then added, the organic phase was extracted 
with EtOAc (3 x 25 ml), dried with Na2SO4 and the solvent was evaporated before the 
crude was purified via flash chromatography to give 14d (trace amounts). TLC 
(Hep/EtOAc 1:1, r.f. = 0.83); 1H NMR (CDCl3): δ 7.79-7.73 (m, 3H, ArH), 7.43 (ddd, 
1H, J = 8.0, 6.8, 1.2, ArH), 7.41 (d, 1H, J = 2.8, ArH), 7.36 (ddd, 1H, J = 8.4, 7.2, 1.6, 
ArH), 7.23 (dd, 1H, J = 8.8, 2.4), 5.47 (d, 1H, J = 4.0, C1-H), 4.57 (dt, 1H, J = 6.0, 
4.4, C3-H), 4.25 (dd, 1H, J = 6.0, 4.0, C2-H), 3.89-3.86 (m, 2H, C5-H), 2.22-2.14 (m, 
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1H, C4-H), 1.99 (dq, 1H, J = 14.8, 4.4, C4-H), 1.56 (s, 3H, i.p.-H), 1.42 (s, 3H, i.p.-
H); 
 
6.2.9. 2-Naphthyl-2,3-O-isopropylidene-4-epi β-D-ribopyranoside (14b) (microwave 
method) 
8 (200 mg, 632 µmol) was dissolved in Ac2O (1.5 ml) and DMSO (3 ml). The solution 
was microwaved for 7 min at 80 oC and H2O (5 ml) was added. The organic phase was 
extracted with CH2Cl2 (3 x 15 ml), washed with brine (40 ml) and dried with Na2SO4 
before the solvent was evaporated. The resulting precipitate was dissolved in dry 
MeOH (15 ml) and the solution was chilled to 0 oC. NaBH4 (74 mg, 1706 µmol) was 
added and the reaction mixture was stirred for 4h and then quenched with H2O (25 
ml). The organic phase was extracted with CH2Cl2 (4 x 50 ml), dried with Na2SO4 and 
the solvent was evaporated to give 8 (94 mg, 297 µmol, 44%). TLC (Hep/EtOAc 1:1, 
r.f. = 0.46); 1H NMR (CDCl3): δ 7.79-7.74 (m, 3H, ArH), 7.46 (ddd, 1H, J = 8.0, 6.8, 
1.2, ArH), 7.42 (d, 1H, J = 2.4, ArH), 7.37 (ddd, 1H, J = 8.0, 6.8, 1.2, ArH), 7.20 (dd, 
1H, J = 8.8, 2.4, ArH), 5.59 (d, 1H, J = 3.2, C1-H), 4.60 (dd, 1H, J = 6.8, 4.4, C3-H), 
4.44 (dd, 1H, J = 6.8, 3.2, C2-H), 4.23-4.16 (m, 1H, C4-H), 3.92 (dd, 1H, J = 11.2, 4.4, 
C5-H), 3.77 (dd, 1H, J = 10.8, 7.6, C5-H), 1.60 (s, 3H, i.p.-H), 1.46 (s, 3H, i.p.-H); 
 
 
6.2.10. 2-Naphthyl-2,3-O-isopropylidene-4-deoxy β-D-ribopyranoside (14d)  
8 (60 mg, 190 µmol) was dissolved in dry THF (4.4 ml) and the solution was chilled 
to 0 oC. 60 % NaH (23 mg, 380 µmol) was added and the reaction mixture was stirred 
for 20 min before being allowed to reach rt. After a further 40 min, CS2 (0.12 ml, 1.90 
mmol) was added. Stirring continued for another hour before MeI (40 µL, 570 µmol) 
was added. 2h later, the solvent was evaporated and the resulting precipitate together 
with AIBN (29 mg, 152 µmol) was partially dissolved in dry toluene (5 ml). n-
Bu3SnH (0.77 ml, 2.85 mmol) was added, the solution was heated to reflux and 
refluxed for 1h. The solvent was evaporated and the crude was purified via flash 
chromatography to give 16 (trace amounts). TLC (Hep/EtOAc 3:1, r.f. = 0.54); 1H 
NMR (CDCl3): δ 7.77 (dd, 3H, J = 14.4, 8.4, ArH), 7.48-7.43 (m, 2H, ArH), 7.38 
(ddd, 1H, J = 8.0, 6.8, 1.2, ArH), 7.24 (dd, 1H, J = 9.2, 2.8, ArH), 6.30-6.26 (m, 1H, 
C4-H), 5.60 (d, 1H, J = 2.4, C1-H), 4.83 (dd, 1H, J = 6.8, 4.0, C3-H), 4.47 (dd, 1H, J = 
6.8, 2.4, C2-H), 4.05-3.96 (m, 2H, C5-H), 2.61 (s, 3H, OMe), 1.63 (s, 3H, i.p.-H), 1.44 
(s, 3H, i.p.-H); 
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